A Pilot Study of Mifepristone in Combat-Related PTSD
Table 1
Clinical and neuroendocrine outcomes.
Pre-treatment
Post-treatment
Between Groups Significance
Initial
Endpoint
4-week
Initial to endpoint
Initial to 4-week
Mean (SD)
Mean (SD)
Mean (SD)
value
value
Clinical
CAPS Score
Drug ()
68.75 (10.24)
43.50 (19.49)
44.00 (24.12)
0.425
0.047
a
Placebo ()
68.25 (8.77)
56.50 (31.89)
65.25 (18.86)
Intrusive Sx
Drug ()
13.75 (8.06)
8.00 (7.70)
7.50 (9.00)
0.463
0.126
Placebo ()
14.50 (4.65)
12.00 (10.30)
15.00 (9.42)
Avoidance Sx
Drug ()
29.25 (7.14)
18.75 (11.44)
17.00 (10.74)
0.239
0.027
b
Placebo ()
28.50 (1.29)
25.50 (7.05)
26.00 (5.72)
Hyperarousal Sx
Drug ()
25.75 (0.50)
16.75 (5.56)
19.50 (9.68)
0.786
0.359
Placebo ()
25.25 (6.40)
18.25 (10.53)
24.25 (5.97)
BDI
Drug ()
22.25 (5.85)
13.25 (4.72)
11.50 (9.15)
0.124
0.769
Placebo ()
24.25 (12.12)
24.75 (10.05)
23.75 (9.54)
PCL
Drug ()
60 (10.83)
46.75 (11.79)
49.25 (15.59)
0.691
0.200
Placebo ()
63.25 (11.41)
54.25 (24.17)
56.25 (16.68)
Neuroendocrine
Cortisol (μg/dL)
Drug ()
13.15 (3.52)
31.28 (5.49)
11.53 (4.27)
0.001
c
0.786
Placebo ()
12.43 (6.16)
12.90 (4.87)
11.83 (2.91)
ACTH (pg/mL)
Drug ()
49.33 (29.69)
153.45 (40.25)
53.63 (8.08)
0.009
d
0.785
Placebo ()
30.88 (14.83)
38.40 (16.18)
41.63 (19.33)
Lysozyme IC50 (nM)
Drug ()
8.00 (2.55)
5.57 (.76)
6.73 (3.66)
0.162
0.411
Placebo ()
3.27 (2.89)
3.65 (2.06)
5.03 (1.68)
GR/cell
Drug ()
1557.67 (539.75)
188.67 (116.89)
1593.00 (770.02)
0.003
0.322
Placebo ()
1019.50 (553.91)
1243.00 (543.84)
1824.75 (683.80)
aMedian change in CAPS score for mifepristone group (20.0); median change in CAPS score for placebo group (10.5); nonparametric value (0.021).
bMedian change in CAPS avoidance symptom score for mifepristone group (11.0); median change in CAPS avoidance symptom score for placebo group (4.0); nonparametric value (0.028).
cMedian change in cortisol for mifepristone group (17.2); median change in cortisol for placebo group (0.4); nonparametric value (0.021).
dMedian change in ACTH for mifepristone group (90.6); median change ACTH for placebo group (4.2); nonparametric value (0.021).
